Trump Orders Vaccine Changes Amid Autism Concerns

President Donald Trump issued an executive order this month to reduce the number of childhood vaccinations from 17 to 11 and separate the measles, mumps, and rubella (MMR) vaccine into three individual shots. The move comes amid Trump's frustration over what he considers a likely contributor to autism and Health Secretary Robert F. Kennedy Jr.'s push for vaccine safety studies.

According to administration officials speaking to Reuters, the order does not substantially change U.S. vaccine policy but is part of a broader effort by Kennedy and his allies to examine what they claim are the dangers of vaccines, including a potential link with autism. Medical experts and scientists have refuted these concerns, citing extensive studies examining millions of children over many years.

Dr. Mehmet Oz, administrator of the Centers for Medicare & Medicaid Services, clarified on CBS's Face the Nation that the MMR vaccine is 'not a lethal vaccine,' despite Trump's claims. The executive order has drawn criticism from leading medical groups, who warn it could increase confusion and vaccine hesitancy among U.S. families, exposing more children to preventable diseases.

The order also directs the Justice Department to challenge state vaccination requirements for children to attend school. However, pharmaceutical companies have noted that separating the MMR vaccine into three shots could take years, as they have not produced separate vaccines in decades. Additionally, a federal judge blocked similar changes proposed by Kennedy earlier this year, ruling that health regulators had acted unlawfully.

Trump's order has sparked tensions within the administration, with political advisers urging Kennedy to avoid public discussions about vaccines ahead of the midterm elections. Despite these requests, Trump has remained focused on reducing vaccinations and finding treatments for autism, according to current and former officials speaking to Reuters. The studies overseen by Kennedy are expected to take months if not longer, adding to Trump's frustration.

CBS News reports that many of the administration's health initiatives rely on voluntary agreements with industry, lacking enforcement mechanisms. These deals have been criticized for their lack of transparency and follow-through, raising questions about their lasting impact. For example, a push to remove certain artificial dyes from food and drugs has seen limited progress, with only a fraction of companies meeting their pledged goals.

The administration's voluntary approach extends to other areas, such as reducing prior authorization requirements for healthcare services. Despite initial promises, progress has been slow, and some insurers have not fully implemented the reforms. The American Medical Association found that only one-third of doctors believed these voluntary pledges would make a meaningful difference.

Despite criticism, the administration continues to tout these voluntary agreements as successes, claiming they deliver significant benefits without heavy-handed regulation. However, the effectiveness and longevity of these initiatives remain uncertain as political attention shifts and public focus wanes.